(NASDAQ: VIRX) Viracta Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Viracta Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast VIRX's revenue for 2026 to be $2,515,006,673, with the lowest VIRX revenue forecast at $624,431,701, and the highest VIRX revenue forecast at $4,405,581,646.
In 2027, VIRX is forecast to generate $6,856,181,528 in revenue, with the lowest revenue forecast at $2,234,601,495 and the highest revenue forecast at $11,477,761,561.